.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,153,856

« Back to Dashboard
Patent 7,153,856 protects SPRYCEL and is included in one NDA. There have been two Paragraph IV challenges on Sprycel.

This patent has sixty-seven patent family members in thirty-eight countries.

Summary for Patent: 7,153,856

Title:Cyclic protein tyrosine kinase inhibitors
Abstract:Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Barrish; Joel C. (Richboro, PA), Wityak; John (Carlsbad, CA), Das; Jagabandhu (Mercerville, NJ), Chen; Ping (Belle Mead, NJ), Norris; Derek J. (Pennington, NJ), Schieven; Gary (Lawrenceville, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/138,942
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 98th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006RXNo7,153,856► subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-002Jun 28, 2006RXNo7,153,856► subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-003Jun 28, 2006RXNo7,153,856► subscribe A METHOD FOR THE TREATMENT OF CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,153,856

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,716,323Cyclic protein tyrosine kinase inhibitors► subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors► subscribe
8,993,567Cyclic protein tyrosine kinase inhibitors► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,153,856

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine87456► subscribe
TaiwanI351404► subscribe
Turkey200102969► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc